Supplement

You have full text access to this OnlineOpen article

Breast pathology guideline implementation in low- and middle-income countries†

  1. Shahla Masood MD1,‡,*,
  2. László Vass MD, PhD2,
  3. Julio A. Ibarra Jr MD3,
  4. Britt-Marie Ljung MD4,
  5. Helge Stalsberg MD5,
  6. Alexandru Eniu MD, PhD6,
  7. Robert W. Carlson MD7,
  8. Benjamin O. Anderson MD8,9,
  9. on behalf of the Breast Health Global Initiative Pathology Focus Group§

Article first published online: 3 OCT 2008

DOI: 10.1002/cncr.23833

Issue

Cancer

Cancer

Supplement: Guidelines for International Breast Health and Cancer Control–Implementation

Volume 113, Issue Supplement 8, pages 2297–2304, 15 October 2008

Additional Information

How to Cite

Masood, S., Vass, L., Ibarra, J. A., Ljung, B.-M., Stalsberg, H., Eniu, A., Carlson, R. W., Anderson, B. O. and on behalf of the Breast Health Global Initiative Pathology Focus Group (2008), Breast pathology guideline implementation in low- and middle-income countries. Cancer, 113: 2297–2304. doi: 10.1002/cncr.23833

Author Information

  1. 1

    Department of Pathology, College of Medicine– Jacksonville, University of Florida, Jacksonville, Florida

  2. 2

    Department of Pathology-Cytopathology, Flor F. University Hospital of Pest County, Budapest, Hungary

  3. 3

    Department of Pathology, Orange Coast Memorial Medical Center, Fountain Valley, California

  4. 4

    Department of Pathology, Division of Cytology, University of California at San Francisco, San Francisco, California

  5. 5

    Department of Pathology, University Hospital of North Norway, Tromsø, Norway

  6. 6

    Department of Breast Tumors, Cancer Institute “Ion Chiricuta,” Cluj-Napoca, Romania

  7. 7

    Department of Internal Medicine, Division of Medical Oncology, Stanford University, Stanford, California

  8. 8

    Department of Surgery, University of Washington, Seattle, Washington

  9. 9

    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

  1. ‡

    Fax: (904) 244-4060

  2. §

    The BHGI Pathology Focus Group members included Shahla Masood (Leader), László Vass, Julio A. Ibarra, Jr, Britt-Marie Ljung, Helge Stalsberg, and R.F. Chinoy (Alexandru Eniu and Robert W. Carlson as invited observers).

*Department of Pathology, University of Florida, 655 West Eighth St., First Floor Clinical Center, Jacksonville, FL 32209

  1. †

    Complete financial disclosures are presented at the end of this article.

Publication History

  1. Issue published online: 3 OCT 2008
  2. Article first published online: 3 OCT 2008
  3. Manuscript Accepted: 24 JUN 2008
  4. Manuscript Received: 10 JUN 2008

Funded by

  • Breast Health Global Initiative Global Summit
  • AstraZeneca
  • Bristol-Myers Squibb
  • Ethicon Endo Surgery
  • GE Healthcare
  • F. Hoffmann-La Roche
  • Novartis Oncology
  • Pfizer

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

REFERENCES

  • 1
    Masood S. The expanding role of pathologists in the diagnosis and management of breast cancer: Worldwide Excellence in Breast Pathology Program. Breast J. 2003; 9( suppl 2): S94–S97.
    Direct Link:
  • 2
    Vargas HI,Anderson BO,Chopra R, et al. Diagnosis of breast cancer in countries with limited resources. Breast J. 2003; 9( suppl 2): S60–S66.
    Direct Link:
  • 3
    Smith RA,Caleffi M,Albert US, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J. 2006; 12( suppl 1): S16–S26.
    Direct Link:
  • 4
    Anderson BO,Yip CH,Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006; 12( suppl 1): S54–S69.
    Direct Link:
  • 5
    Eniu A,Carlson RW,Aziz Z, et al. Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J. 2006; 12( suppl 1): S38–S53.
    Direct Link:
  • 6
    Shyyan R,Masood S,Badwe RA, et al. Breast cancer in limited-resource countries: diagnosis and pathology. Breast J. 2006; 12( suppl 1): S27–S37.
    Direct Link:
  • 7
    Anderson BO,Shyyan R,Eniu A, et al. Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J. 2006; 12( suppl 1): S3–S15.
    Direct Link:
  • 8
    Stalsberg HS,Awuah B,Ibarra JA,Nsiah-Asare A. Reestablishing a surgical pathology service in Kumasi, Ghana: case report and discussion of barriers and key elements of a successful collaboration between low- and high-resource countries. Cancer. 2008; 113( suppl 8): 2338–2346.
    Direct Link:
  • 9
    Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991; 15: 209–221.
  • 10
    Schnitt SJ,Connolly JL,Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992; 16: 1133–1143.
  • 11
    Masood S. Standard guidelines for breast fine-needle aspiration biopsy: a new challenge. Breast J. 1996; 2: 231–232.
    Direct Link:
  • 12
    Lanin DR,Silverman JF,Walker C, et al. Cost-effectiveness of needle biopsy of the breast. Am Surg. 1986; 203: 474–480.
  • 13
    Abati A,Simsir A. Breast fine needle aspiration biopsy: prevailing recommendations and contemporary practices. Clin Lab Med. 2005; 25: 631–654.
  • 14
    Masood S. Core needle biopsy versus fine needle aspiration biopsy: are there similar sampling and diagnostic issues? Clin Lab Med. 2005; 25: 679–688.
  • 15
    Vargas H,Masood S. Implementation of a minimally invasive breast biopsy program in countries with limited resources. Breast J. 2003; 9: S81–S85.
    Direct Link:
  • 16
    Silverberg SG,Masood S. The breast. In: SilverberSC, ed. Principles and Practice of Surgical Pathology and Cytopathology.3rd ed. London: Churchill Livingstone; 1997: 575–673.
  • 17
    Staradub VL,Messenger KA,Hao N, et al. Changes in breast cancer therapy because of pathology second opinions. Ann Surg Oncol. 2002; 9: 982–987.
  • 18
    Masood S. Raising the bar: a plea for standardization and quality improvement in the practice of breast pathology. Breast J. 2006; 12: 409–412.
    Direct Link:
  • 19
    Titus K. In breast cancer diagnosis, don't balk at talk. CAP Today. 2007; 21: 1.
  • 20
    Newman E,Guest A,Helvie M, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 2006; 107: 2346–2351.
    Direct Link:
  • 21
    Demartines N,Mutter D,Vix M, et al. Assessment of telemedicine in surgical education and patient care. Ann Surg. 2000; 231: 282–291.
  • 22
    Henson DE,Oberman HA,Hutter RV. Practice protocol for the examination of specimens removed from patients with cancer of the breast: a publication of the Cancer Committee, College of American Pathologists. Members of the Cancer Committee, College of American Pathologists, and the Task Force for Protocols on the Examination of Specimens from Patients with Breast Cancer. Arch Pathol Lab Med. 1997; 121: 27–33.
  • 23
    Wilkinson NW,Shahryarinejad A,Winston JS, et al. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg. 2003; 196: 38–43.
  • 24
    Wells WA,Carney PA,Eliassen MS, et al. Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst. 1998; 90: 142–145.
  • 25
    Masood S. Standardization of immunobioassays as surrogate endpoints. J Cell Biochem Suppl. 1994; 19: 28–35.
  • 26
    Paik S,Bryant J,Tan-Chiu E, et al. Real-world performance of HER2 testing—National surgical adjuvant breast and bowel project experience. J Natl Cancer Inst. 2002; 94: 852–854.
  • 27
    Roche PC,Suman VJ,Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002; 94: 855–857.
  • 28
    Rhodes A,Jasani B,Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000; 53: 125–130.
  • 29
    Shyyan R,Sener SF,Anderson BO, et al. Guideline implementation for breast health care in low and middle-income countries: treatment resource allocation. Cancer. 2008; 113( suppl 8): 2257–2268.
    Direct Link:
  • 30
    Wolff AC,Hammond ME,Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118–145.
  • 31
    Veronesi U,Paganelli G,Galimberti V, et al. Sentinel node biopsy can avoid axillary dissection in breast cancer patients with clinically negative lymph nodes. Lancet. 1997; 349: 1864–1867.
  • 32
    Viale G,Maiorano E,Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005; 241: 319–325.
  • 33
    Giuliano AE,Kirgan DM,Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220: 391–401.
  • 34
    Hakam A,Khin NN. Intraoperative imprint cytology in assessment of sentinel lymph nodes and lumpectomy surgical margins. Clin Lab Med. 2005; 25: 795–807.
  • 35
    Masood S. Why a new society? A call for action: advancing knowledge in breast pathology. Breast J. 2003; 9: 263–265.
    Direct Link:
  • 36
    Masood S. The fine line between competency and quality performance in breast pathology: are we serving our patients right? Breast J. 2007; 13: 441–442.
    Direct Link:
  • 37
    Masood S. Integration of professionalism and volunteerism in building the foundation of the “International Institute of Breast Pathology.” A worldwide collaboration. Breast J. 2008; 14: 125–127.
    Direct Link:
View Full Article (HTML) Get PDF (101K)